Abstract:Objective Inhaled nitric oxide(iNO) has been used in preterm infants with hypoxic respiratory failure (HRF). However, there is controversy about its therapeutic effect. In this article, the studies of iNO for HRF were summarized and the effect of iNO for HRF was assessed in preterm infants using meta-analysis method. Methods Medical electronic databases and other sources were searched without language restriction. According to inclusion and exclusion cretria, articles were evaluated (Shekelle PG, et al). RCTs were assessed according to the Juni assessment. Software Rev Man 4.2 was used to assess control trials, and other studies were reviewed and descrbied. Results Nine RCTs with 6 blind trials and 3 non-blind trials were selected from 883 articles. Publication bias was not found through funnel polt analysis. There were 3 RCTs that compared the oxygen use and the duration of ventilation, the length of hospitalization, including 259 patients in iNO and 259 in the control group. Compared to the control group, iNO could reduce the oxygen use (WMD=-10.24,95%CI:-19.62,-0.86,P0.05); There was no difference in the duration of ventilation between iNO and the control group (WMD=-4.87,95%CI:-10.68,0.94,P0.05); Compared to the control group, iNO could reduce the length of hospitalization (WMD=-8.31,95%CI:-16.23,-0.38,P0.05). There were 6 RCTs that compared the death before discharge, including 1084 patients in iNO and 1096 in the control group. There was no difference in the deaths before discharge between iNO and the control group (OR=0.95,95%CI:0.77,1.17,P0.05). There were 5 RCTs that compared the incidence of BPD among survivors at 36 weeks, including 618 patients in iNO and 621 in the control group. Compared to the control group, iNO could reduce the incidence of BPD (OR=0.75,95%CI:0.58,0.95,P0.05). There was no difference in the incidence of intraventricular hemorrhage (all grades) between iNO and the control group (OR=0.79,95%CI:0.62,1.00,P=0.05). There were 4 RCTs that compared the incidence of intraventricular hemorrhage (grade 3 or 4), including 767 patients in iNO and 784 in the control group. Compared to the control group, iNO could reduce the incidence of intraventricular hemorrhage (grade 3 or 4) (OR=0.84,95%CI:0.61,1.16,P0.05). There were 5 RCTs that compared the intraventricular hemorrhage (grade 3 or 4) or periventicular leukomacia, including 1021 patients in iNO and 1012 in the control. There was no difference in the incidence of intraventricular hemorrhage (grade 3 or 4) or periventicular leukomacia between iNO and the control group (OR=0.95,95%CI:0.68,1.22,P0.05). There were 2 RCTs that compared the incidence of threshold ROP, including 608 patients in iNO and 605 in the control group. There was no difference in the incidence of threshold ROP between iNO and the control group (OR=0.98,95% CI:0.72,1.34,P0.05). There were 4 RCTs that compared the incidence of ROP, including 474 patients in iNO and 463 in the control group. There was no difference in the incidence of ROP between iNO and the control group (OR=1.08,95%CI:0.75,1.57,P0.05). There was 1 RCT that compared the incidence of ROP requiring surgery, including 294 patients in iNO and 288 in the control group. There was no differencein the incidence of ROP requiring surgery between iNO and the control group(OR=1.05,95%CI:0.72,1.53, P0.05). There were 3 RCTs that compared the incidence of cerebral palsy, including 168 patients in iNO and 184 in the control group. There was no difference in the incidence of cerebral palsy between iNO and the control group (OR=1.08,95%CI:0.75,1.57,P0.05). There were 2 RCTs that compared the incidence of Bayley MDI2SD, including 156 patients in iNO and 110 in the control group. There was no difference in the incidence of Bayley MDI2SD between iNO and the control group (OR=0.84,95%CI:0.50,1.42,P0.05). There were 2 RCTs that compared the incidence of Bayley PDI2SD, including 155 patients in iNO and 167 in the control group. There was no difference in the incidence of Bayley PDI2SD between iNO and the routine therapy group (OR=0.94,95%CI:0.57,1.58,P0.05). Conclusions The currently published evidence from randomised trials does not support the routine use of iNO in preterm infants with HRF. Further multicentre and large-scale RCTs are still needed to be performed to evaluate the potential benefit of iNO as routine therapy in preterm infants with HRF, and these trials need to be designed to evaluate not only the short term effects, but should be powered to evaluate neurondevelopmental outcome at a minimum of two years of age.

Use of inhaled nitric oxide in submassive intermediate-risk pulmonary embolism: a single-centre experience

Inhaled Nitric Oxide in Preterm and Term Neonates with Hypoxemic Respiratory Failure and Persistent Pulmonary Hypertension

Massive Pulmonary Embolism in a Recent Intracranial Hemorrhage: A Case Report of Inhaled Nitric Oxide to Improve Outcomes

Impact of inhaled nitric oxide therapy in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation combined with Impella

More questions than answers for the use of inhaled nitric oxide in COVID-19

New Modalities for the Administration of Inhaled Nitric Oxide in Intensive Care Units After Cardiac Surgery or for Neonatal Indications: A Prospective Observational Study

The early use of inhaled nitric oxide in premature infants requiring respiratory support

The Off-Label Use of Inhaled Nitric Oxide as a Rescue Therapy in Neonates with Refractory Hypoxemic Respiratory Failure: Therapeutic Response and Risk Factors for Mortality

Inhaled nitric oxide as a rescue therapy in a preterm neonate with severe pulmonary hypertension: a case report

Inhalation of Nitric Oxide in Congenital Heart Defects Associated with Pulmonary Hypertension

Impact of inhaled nitric oxide therapy in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation combined with Impella: a retrospective cohort study

Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial

Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery

Randomized, Controlled Trial of Low-dose Inhaled Nitric Oxide in the Treatment of Term and Near-term Infants With Respiratory Failure and Pulmonary Hypertension

Impact of Inhaled Nitric Oxide (iNO) on the Outcome of COVID-19 Associated ARDS

Noninvasive inhaled nitric oxide for persistent pulmonary hypertension of the newborn: A single center experience

Safety of inhaled nitric oxide withdrawal in severe chronic pulmonary hypertension

Nitric oxide for the treatment of preterm infants with severe RDS and pulmonary hypertension

Inhaled nitric oxide in newborns with severe hypoxic respiratory failure

The acute effect of inhaled nitric oxide on the exercise capacity of patients with advanced interstitial lung disease: a randomized controlled trial

Meta-analysis of Inhaled Nitric Oxide for Hypoxaemic Respiratory Failure in Preterm Infants